1. Can statin preventative treatment inform geroscience‐guided therapeutics?
- Author
-
Guaraldi, Giovanni, Erlandson, Kristine M., Milic, Jovana, Landay, Alan L., and Montano, Monty A.
- Subjects
STATINS (Cardiovascular agents) ,MAJOR adverse cardiovascular events ,PITAVASTATIN ,THERAPEUTICS ,HIV-positive persons - Abstract
The article discusses the potential benefits of statin treatment in preventing and reducing frailty, particularly in people with HIV (PWH) who are at a higher risk of cardiovascular disease (CVD) and accelerated aging. The REPRIEVE study, which focused on PWH without pre-existing CVD, found that treatment with pitavastatin reduced the risk of major adverse cardiovascular events (MACE) compared to a placebo. The study suggests that statins may have a geroprotective effect by targeting senescence, a key factor in age-related conditions. However, it also acknowledges the potential adverse effects of statins and the need for further research on their mechanisms of action. The findings from the REPRIEVE study may lead to earlier initiation of statin therapy in PWH and have implications for geroscience-guided therapeutics. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF